From: NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients
Fraction of DTCs categorized as NR2F1high | Distant metastasis (all) or death from breast cancer (%) | Bone metastasisb (%) | ||
---|---|---|---|---|
All patientsa (n = 26) | < 50% | 0 to < 50% NR2F1high | 17/19 (89.5) | 10/15 (66.7) |
0–1% NR2F1high | 13/15 (86.7) | 9/14 (64.3) | ||
50–100% | 4/7 (57.1) | 2/7 (28.6) | ||
Patients without metastasis prior to last DTC-positive BMA and no negative DTC status at subsequent BMA (n = 18) | < 50% | 0 to < 50% NR2F1high | 13/14 (92.9) | 9/12 (75.0) |
0–1% NR2F1high | 11/12 (91.7) | 8/11 (72.7) | ||
50–100% | 1/4 (25.0) | 1/4 (25.0) | ||
Patients with no metastasis at time point for last DTC-positive BMA, no negative DTC status at subsequent BMA, and no chemotherapy after the BM analysis (n = 14) | < 50% | 0 to < 50% NR2F1high | 11/12 (91.7) | 7/10 (70.0) |
0–1% NR2F1high | 9/10 (90.0) | 6/9 (66.7) | ||
50–100% | 1/2 (50.0) | 1/2 (50.0) |